| pubmed-article:15045953 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15045953 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:15045953 | lifeskim:mentions | umls-concept:C0278554 | lld:lifeskim |
| pubmed-article:15045953 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:15045953 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:15045953 | lifeskim:mentions | umls-concept:C0048808 | lld:lifeskim |
| pubmed-article:15045953 | lifeskim:mentions | umls-concept:C0868928 | lld:lifeskim |
| pubmed-article:15045953 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:15045953 | lifeskim:mentions | umls-concept:C0701185 | lld:lifeskim |
| pubmed-article:15045953 | lifeskim:mentions | umls-concept:C2003874 | lld:lifeskim |
| pubmed-article:15045953 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:15045953 | pubmed:dateCreated | 2004-3-29 | lld:pubmed |
| pubmed-article:15045953 | pubmed:abstractText | We performed combined chemotherapy of low-dose CPT-11 and 5'-DFUR as second-line chemotherapy in 2 cases of non-resectable metastatic or recurrent rectal cancer. The first patient was a 61-year-old male who had rectal cancer with liver and lung metastases. The second patient was a 76-year-old male who had initial recurrent rectal cancer with multiple liver metastases. Both patients were given first-line chemotherapy of 5-FU + l-LV. CPT-11 was administered at 60 mg/body on day 1, 8 and 15 of a 4-week course by intravenous infusion as outpatient treatment. Furthermore, 5'-DFUR was administered orally at 800 mg/body every day. Consequently, we obtained a decrease in the tumor markers and a reduction of liver metastases in 2 patients after 3 months, Adverse reactions such as myelosuppression and diarrhea were not observed. This treatment could be continued in safety with good QOL on an outpatient basis. These cases suggest that this combined chemotherapy of low-dose CPT-11 and 5'-DFUR may be an effective treatment for non-resectable colorectal cancer in the future. | lld:pubmed |
| pubmed-article:15045953 | pubmed:language | jpn | lld:pubmed |
| pubmed-article:15045953 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15045953 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15045953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15045953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15045953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15045953 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15045953 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15045953 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:15045953 | pubmed:issn | 0385-0684 | lld:pubmed |
| pubmed-article:15045953 | pubmed:author | pubmed-author:SuzukiMasaaki... | lld:pubmed |
| pubmed-article:15045953 | pubmed:author | pubmed-author:TakahashiMako... | lld:pubmed |
| pubmed-article:15045953 | pubmed:author | pubmed-author:NakanoMakotoM | lld:pubmed |
| pubmed-article:15045953 | pubmed:author | pubmed-author:ShimizuHideoH | lld:pubmed |
| pubmed-article:15045953 | pubmed:author | pubmed-author:HaraguchiYosh... | lld:pubmed |
| pubmed-article:15045953 | pubmed:author | pubmed-author:OkusawaAtsush... | lld:pubmed |
| pubmed-article:15045953 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15045953 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:15045953 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15045953 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15045953 | pubmed:pagination | 419-22 | lld:pubmed |
| pubmed-article:15045953 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15045953 | pubmed:meshHeading | pubmed-meshheading:15045953... | lld:pubmed |
| pubmed-article:15045953 | pubmed:meshHeading | pubmed-meshheading:15045953... | lld:pubmed |
| pubmed-article:15045953 | pubmed:meshHeading | pubmed-meshheading:15045953... | lld:pubmed |
| pubmed-article:15045953 | pubmed:meshHeading | pubmed-meshheading:15045953... | lld:pubmed |
| pubmed-article:15045953 | pubmed:meshHeading | pubmed-meshheading:15045953... | lld:pubmed |
| pubmed-article:15045953 | pubmed:meshHeading | pubmed-meshheading:15045953... | lld:pubmed |
| pubmed-article:15045953 | pubmed:meshHeading | pubmed-meshheading:15045953... | lld:pubmed |
| pubmed-article:15045953 | pubmed:meshHeading | pubmed-meshheading:15045953... | lld:pubmed |
| pubmed-article:15045953 | pubmed:meshHeading | pubmed-meshheading:15045953... | lld:pubmed |
| pubmed-article:15045953 | pubmed:meshHeading | pubmed-meshheading:15045953... | lld:pubmed |
| pubmed-article:15045953 | pubmed:meshHeading | pubmed-meshheading:15045953... | lld:pubmed |
| pubmed-article:15045953 | pubmed:meshHeading | pubmed-meshheading:15045953... | lld:pubmed |
| pubmed-article:15045953 | pubmed:meshHeading | pubmed-meshheading:15045953... | lld:pubmed |
| pubmed-article:15045953 | pubmed:meshHeading | pubmed-meshheading:15045953... | lld:pubmed |
| pubmed-article:15045953 | pubmed:meshHeading | pubmed-meshheading:15045953... | lld:pubmed |
| pubmed-article:15045953 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15045953 | pubmed:articleTitle | [Two cases of metastatic or recurrent rectal cancer responding to combined chemotherapy of low-dose CPT-11 and 5'-DFUR as second-line chemotherapy]. | lld:pubmed |
| pubmed-article:15045953 | pubmed:affiliation | Dept. of Surgery, Matsumura General Hospital. | lld:pubmed |
| pubmed-article:15045953 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15045953 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:15045953 | pubmed:publicationType | Case Reports | lld:pubmed |
